Neratinib and metformin: A novel therapeutic approach against HER2-Positive Breast Cancer
These findings suggest that neratinib and metformin combination can present a promising strategy for targeting multiple pathways in HER2-positive BC.
Authors
- Hamda Al-Thawadi
- Monika Ulamec (ORCID: https://orcid.org/0000-0002-4843-8154)
- Hadeel Kheraldine (ORCID: https://orcid.org/0000-0002-9498-9387)
- Jericha Miles Pamiloza Mateo
- Semir Vranić (ORCID: https://orcid.org/0000-0001-9743-7265)
- Maysaloun Merhi (ORCID: https://orcid.org/0000-0002-8016-3699)
- Melita Perić Balja (ORCID: https://orcid.org/0000-0002-4871-9677)
- Arij Fouzat Hassan (ORCID: https://orcid.org/0000-0002-2012-4153)
- Ala‐Eddin Al Moustafa
- S Saeed
Institutions
- University Hospital Centre Zagreb (HR)
- McGill University Health Centre (CA)
- Sisters of Charity Hospital (HR)
- Hamad Medical Corporation (QA)
- McGill University (CA)
- Qatar University (QA)
Publication Details
- Journal
- Biomedicine & Pharmacotherapy
- Published
- 2025-04-17
- DOI
- https://doi.org/10.1016/j.biopha.2025.118034
- Citations
- 1
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 1.05
Funders
- Qatar National Research Fund